Ergosta-7,22-dien-6-one, 3,5-dihydroxy-, (3β,5α,22E)-

Ergosta-7,22-dien-6-one, 3,5-dihydroxy-, (3β,5α,22E)- - Names and Identifiers

Name	3,5-Dihydroxyergosta-7,22-dien-6-one
Synonyms	22-dien-6-one 5-Dihydroxyergosta-7 6-Dehydrocerevisterol 3,5-Dihydroxyergosta-7,22-dien-6-one 3β,5α-Dihydroxyergosta-7,22-dien-6-one 5alpha-Ergosta-7,22-diene-3beta,5beta-diol-6-one Ergosta-7,22-dien-6-one, 3,5-dihydroxy-, (3β,5α,22E)- (22E,24R)-3beta,5alpha-dihydroxyergosta-7,22-dien-6-one
CAS	14858-07-2

Ergosta-7,22-dien-6-one, 3,5-dihydroxy-, (3β,5α,22E)- - Physico-chemical Properties

Molecular Formula	C28H44O3
Molar Mass	428.65
Appearance	Powder
Storage Condition	2-8℃

Ergosta-7,22-dien-6-one, 3,5-dihydroxy-, (3β,5α,22E)- - Introduction

3,5-dihydroxyergosta-7, 22-dien-6-one is also known as 3,5-dihydroxyergosta-7, 22-dien-6-one. It is a kind of plant sterols compounds, has certain biological activity.

Regarding the properties of 3,5-dihydroxyergosta-7, 22-dien-6-one, it is a crystalline solid that is soluble in organic solvents such as ethanol and dimethylformamide at room temperature, but insoluble in water. It has a skeleton structure similar to cholesterol and contains two hydroxyl groups at positions 3 and 5, a ketone group at position 6, and a double bond at positions 7 and 22.

In Terms of Use, 3,5-dihydroxyergosta-7, 22-dien-6-one has antioxidant, anti-inflammatory and immunomodulatory biological activities. It is widely used in the field of medicine and health care products for the treatment of chronic inflammatory diseases, tumors and immune system diseases.

Regarding the production method, 3,5-dihydroxyergosta-7, 22-dien-6-one can be obtained by biosynthesis or chemical synthesis. Biosynthesis, among others, utilizes fungal or plant cell culture to produce the compound. The methods of chemical synthesis involve different reaction steps and reaction conditions, including oxidation, reduction, acylation, etc.

In terms of safety information, due to the lack of sufficient toxicology data and clinical studies, the current understanding of the safety of 3,5-dihydroxyergosta-7, 22-dien-6-one is limited. Therefore, relevant safety operation procedures should be followed during use, and risks should be assessed and controlled according to specific conditions.

Last Update：2024-04-09 21:54:55